General information, not individual medical advice. This article cannot take account of your medical history, medicines or circumstances. Speak to a GP, pharmacist or other healthcare professional before making significant changes to what you eat or to any treatment, particularly if you have a medical condition, follow a prescribed diet, take medicines affected by food intake, are pregnant or breastfeeding, or have an eating disorder now or in the past.
Most questions about Mounjaro side effects start with the stomach. That is understandable: nausea, diarrhoea, vomiting, constipation and abdominal discomfort are among the effects most often reported. For many people they are mild or moderate and are more likely during dose increases, often easing with time. "Common" does not mean unimportant, though: persistent vomiting or diarrhoea can make it difficult to stay hydrated.
Mounjaro (tirzepatide) is a prescription medicine. Whether it is suitable depends on a person's health, other medicines, treatment goals and ability to tolerate it. The current UK product information and the patient leaflet should be the first reference for an individual decision.
Common effects and what to do
The most frequent problems are gastrointestinal: nausea, diarrhoea, vomiting, constipation, abdominal pain or discomfort, indigestion, bloating, burping and reflux. In weight-management trials, several of these are classed as "very common" in the UK label, meaning they were reported in at least 1 in 10 people in the relevant trial data; exact rates vary by symptom, dose and study. Reduced appetite is part of the drug's intended effect. Some people also report fatigue, dizziness, hair loss or injection-site reactions. Nausea, diarrhoea and vomiting tend to occur particularly during dose escalation and decrease over time; that pattern is not a reason to ignore symptoms that are severe or persistent. See the UK Summary of Product Characteristics for the full safety profile.
If nausea makes meals difficult, smaller portions may feel easier than a large meal. If vomiting or diarrhoea means you cannot keep fluids down, seek medical advice rather than trying to push through. Dehydration can affect kidney function, especially in people who are older or already have kidney problems.
Warning signs that need urgent attention
Get urgent medical help for severe or persistent abdominal pain, especially pain that travels through to the back; for significant upper-abdominal pain with fever or yellowing of the skin or eyes; or for sudden swelling, breathing difficulty or collapse. In an emergency call 999. For urgent advice that is not an emergency, call NHS 111.
Severe, persistent abdominal pain, especially pain that travels through to the back, needs urgent medical assessment. Pancreatitis is an infrequent but potentially serious risk; the MHRA strengthened warnings in January 2026 after reviewing reports that included severe and fatal cases. If pancreatitis is suspected, the medicine should be stopped while a clinician assesses the person. The MHRA's current patient advice describes the warning signs.
Gallstones and gallbladder inflammation have also been reported. Get prompt medical advice for significant upper-abdominal pain, fever, yellowing of the skin or eyes, or pain that does not settle. The product information also lists severe allergic reactions as rare; sudden swelling, breathing difficulty or collapse requires emergency help.
The MHRA Yellow Card system collects suspected side-effect reports. Those reports help identify possible safety signals, but they do not show how often an effect occurs among all users. A report is not, by itself, proof that the medicine caused the event.
Low blood sugar: who is most at risk?
Tirzepatide on its own does not usually cause low blood sugar in the same way as insulin. The risk is higher when it is used with insulin or a sulphonylurea medicine. People with diabetes taking those combinations may need their diabetes team to review doses and glucose monitoring. Do not reduce insulin or another diabetes medicine without clinical advice.
Pregnancy, contraception and surgery
Current MHRA public guidance says not to use GLP-1 medicines such as Mounjaro during pregnancy, while trying to become pregnant or while breastfeeding. If planning a pregnancy, stop tirzepatide at least one month beforehand and discuss the plan with a clinician. If you take the contraceptive pill, add a barrier method for four weeks after starting Mounjaro and for four weeks after every dose increase, or discuss a non-oral contraceptive method. Tirzepatide can affect absorption of oral medicines because it delays stomach emptying. Read the MHRA's current guidance on pregnancy and contraception.
Tell the anaesthetist and wider surgical team if you use Mounjaro before an operation or procedure involving general anaesthesia or deep sedation. Delayed stomach emptying can affect aspiration risk and the team may need to adjust its plan. Do not stop the medicine around a procedure unless the clinical team tells you to.
Does "long-term side effects" mean long-term use is unsafe?
It is sensible to ask what is known over years, not only during the first few months. The medicine has been studied in large trials and continues to be monitored after authorisation, but no webpage can predict an individual's long-term balance of benefit and harm. The right question for a prescriber is: what will we monitor, how will we decide whether it is still helping, and what is the plan if I cannot continue?
Sources
- Mounjaro UK Summary of Product Characteristics
- MHRA: GLP-1 medicines for weight loss and diabetes
- MHRA: strengthened warnings on acute pancreatitis
- NHS: Tirzepatide
Links checked on 25 September 2026.
Date Written:
12/06/2026
Role:
Clinical Pharmacist
Date Checked:
12/06/2026
Role:
Pharmacist
Wondering whether treatment is an option?
Check your BMI against the UK eligibility thresholds, or complete a free online assessment and a GPhC-registered prescriber will review whether treatment is appropriate for you.